This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.
INTERCHANGEABILITY
The primary aim of drug interchangeability in North America is to reduce costs without compromising patient care (i.e. drug acquisition cost) (1) . There are two types of drug interchangeability: a) therapeutic, and b) generic. Therapeutic interchangeability is the substitution of chemically unique drugs that have evidence of therapeutic equivalence (1) . Therapeutically equivalent drugs may be interchanged or used as substitutes because they will produce almost identical therapeutic outcomes and adverse reactions (2) . Guidelines are usually provided to assist with therapeutic interchangeability (substitutions) for specific medical conditions.
There are six criteria for scientifically justifiable and pharmacoeconomically beneficial therapeutic interchangeability (1) . If chemically unique drugs fail to meet any one of the six fol-lowing criteria, then therapeutic interchangeability is not recommended (1):
1. Pharmacologic equivalence 2. Clinical evidence supporting the therapeutic interchange 3. Cost (or other advantages) 4 . Thorough evaluation process (e.g., Pharmacy and Therapeutics Committee) 5. Regular monitoring of patient outcomes 6. Occurrence for variance
There are heated debates about therapeutic interchangeability for low-molecular-weight heparins (LMWHs) (1, (3) (4) (5) . The brand name LMWH products, such as dalteparin (Fragmin®), enoxaparin (Lovenox®), nadroparin (Fraxi-parin®), and tinzaparin (Innohep®), are chemically and biologically unique drugs (6) (7) (8) .
The other type of drug interchangeability is generic interchangeability, which refers to the substitution of a drug chemically identical and bioequivalent to the brand name (original, pioneer) drug. For example, one original drug has the generic name of warfarin, the brand name of Coumadin®, and the generic product name of Taro-Warfarin®. At this time, a generic equivalent product of a branded LMWH is not available.
The United States Food and Drug Administration (FDA) approves approximately 250 generic drugs per year.
LMWHS ARE DISTINCT ENTITIES AND THERAPEUTICALLY NON-INTERCHANGEABLE DRUGS
The class of LMWHs has not received status as a therapeutically non-interchangeable drug (although it is recommended that they not be used interchangeably, at least on a unit-for-unit basis). Examples of traditional non-interchangeable drugs in North America include L-thyroxine and digoxin.
Is each LMWH a chemically and therapeutically unique antithrombotic agent that may not be interchanged? The answer is 100% clear: YES. In 1993, the World Health Organization (WHO) has acknowledged that each LMWH is a distinct entity. LMWH non-interchangeability has also been supported by the FDA, the American College of Chest Physicians (ACCP), the American College of Cardiology (ACC), and the American Heart Association (AHA) (9) (10) (11) (12) .
Chemical versus enzymatic degradation of heparin clearly affects antithrombotic activity, such as anti-Xa activity, anti-IIa activity, platelet aggregation, etc. (7, 12, 13) . But what is the clinical significance of these changes? Positive clinical outcomes with one LMWH may not be generalized to other LMWHs. Pharmacologic equivalence between LMWHs has not been proven because direct LMWH comparison studies are not readily available (1) . For example, the ESSENCE study has established enoxaparin dosage at 1 mg/kg subcutaneously twice daily for the management of acute coronary syndrome (14) . In contrast, the studies on dalteparin demonstrated its efficacy in this syndrome at 120 U/kg twice daily, which amounts to a lower dosage in milligrams per kilogram (0.8 mg/kg) in this patient population (FRIC, FRISC studies) (15, 16) . Thus, the dosages of the two different LMWHs were different in these studies. Regardless of the debates, LMWHs are not therapeutically interchangeable, according to the WHO, FDA, ACC, and AHA (9) (10) (11) (12) .
Generic interchangeability between a brand name and generic LMWH has yet to be established. Clearly the data must extend beyond basic bioequivalence, due to the complex pharmacodynamic profile of LMWHs (12, 17) . At this time there are no clear guidelines for the regulatory bodies to compare the generic version of branded LMWHs.
THE FDA GENERIC APPROVAL PROCESS In 1984, the U.S. Congress passed the Drug Price Competition and Patent Term Restoration Act (wwwfda.gov). The Act expanded the number of drugs eligible to be manufactured as generics by eliminating the need for duplicate safety and efficacy testing, saving the pharmaceutical company producing the generic version of branded drugs both time and money. It is stipulated that a bioequivalent generic drug would produce similar safety and efficacy benefits as the brand name product.
Currently According to the FDA, bioequivalency is a mandatory requirement for generic drugs. Bioequivalency is a demonstration of acceptable parameters established for bioavailability (i.e., the extent and rate of drug absorption). Bioequivalency does not require the replication of clinical trials by generic drugs that were originally established by the brand name drug. Bioequivalence studies usually include assay validation, dissolution studies, and in vitro and in vivo testing of the generic drugs.
A generic drug manufacturer must provide the pharmacokinetic data of its product for comparison with the original brand name product. Traditionally, the pharmacokinetic (ADME) profile of a drug includes: * Absorption (e.g., oral bioavailability) * Distribution (e.g., plasma protein binding) * Metabolism (e.g., active metabolites, cytochrome P450 enzymes) * Elimination (e.g., renal and/or hepatic elim-
On a daily basis, the general public continues to ask pharmacists and other health care professionals if generic drugs are as good as brand name drugs. Does a cheaper generic drug mean an inferior product?
Currently, the FDA approves approximately 250 generic drugs per year. In 1989, generic drugs were scrutinized heavily by federal investigators. There were reports of noncompliance, fraud, obstruction of justice, and illegal gratuities by some generic pharmaceutical manufacturers (same occurs with manufacturers of name brand products). This undermined confidence in generic products and the generic approval process. The review process by the FDA and other regulatory bodies is therefore an important factor in the acceptance of generic LMWHs. However, at this time specific guidelines for the review process are not clear.
GENERIC ANTITHROMBOTIC DRUGS
Two examples of antithrombotics with generic products in North America are warfarin and unfractionated heparin (UH). Another complex antithrombotic drug with a unique manufacturing process is alteplase (tissue plasminogen activator [tPA] ). This fibrinolytic agent is produced via recombinant DNA technology. Generic tPA is still not available in 2003, perhaps due to the extensive manufacturing process and its associated costs. However, like the LMWHs, different molecular forms of tPA with biochemical and pharmacologic differences are now available. Each of the different tPA preparations produce different lytic effects and have been clinically tested in specific trials.
Recently, there has been opposition to generic LMWH applications in the United States. The strongest argument relies on the unique LMWH manufacturing process, and the lack of "full characterization" of this drug class. However, other antithrombotic drugs with equally complicated bioequivalence and pharmacodynamic data with FDA generic approval are warfarin and unfractionated heparin.
Warfarin is an oral anticoagulant that was originally marketed by Dupont (now Bristol Myers Squibb) under the brand name of Coumadin®. Warfarin is also considered a complex antithrombotic agent affecting all of the four vitamin K-dependent factors (II, VII, IX, X) (18) .
Each factor has its own half-life, varying from 4 to 72 hours. Laboratory monitoring is required to maintain a therapeutic International Normalized Ratio (INR) in the range of 2.0 to 3.0 or 2.5 to 3.5 (depending on the warfarin indication) (18) . Some scientists could argue that warfarin has not been fully characterized over the past 40 years. Traditionally warfarin was considered a non-interchangeable drug. Two generic warfarin products are now available: Taro-WarfarinO (United States and Canada) and Apo-Warfarin (Canada). Taro Pharmaceuticals USA Inc. obtained FDA approval for generic warfarin (ANDA 40-301) in June 1999.
UH is a rather complex drug with even less known "full characterization." Not only is this agent heterogeneous in nature but it also produces polypharmacologic actions that are not fully understood. However, generic UH sodium injection produced by American Pharmaceutical Partners Inc. was approved by the FDA in March 2002 (ANDA 17-029/S-099).
GENERIC LMWH APPROVAL PROCESS
Two generic LMWH are currently available in India, sold under the brand name of Cutenox® (enoxaparin) and Markaparin (enoxaparin). Generic versions of enoxaparin have also been introduced in South Asian countries. In the United States, two generic drug manufacturers, Amphastar and Teva Pharmaceuticals, have filed for FDA review of a generic version of enoxaparin. Several other companies are expected to follow soon. Generic LMWH in North America is inevitable due to cost containment pressures in the hospital setting. Due to the current regulatory guidelines, generic interchangeability is more acceptable and less stringent than therapeutic LMWH interchangeability.
A citizen's petition from one LMWH manufacturer in the United States (Aventis Pharmaceuticals) against generic approval emphasized the unique manufacturing process for its LMWH and its effect on antithrombotic activity and clinical outcomes. There is no argument that chemical versus enzymatic degradation clearly affects antithrombotic activity. It would appear that a generic LMWH company must duplicate, exactly, the brand LMWH's manufacturing process and provide physicochemical and biologic data on the product equivalence.
Systematic studies involving physicochemical, biologic, and pharmacologic profiling should be considered a prerequisite for the acceptance of a generic versions of a branded product. Because of the recent availability of generic forms of enoxaparin a comparative study utilizing various standard methods, a branded agent, namely enoxaparin was compared with the available generic forns. The preliminary results of the recently completed studies are summarized in the following: * The currently available brand-name LMWHs in the United States include dalteparin (Pfizer), enoxaparin (Aventis), and tinzaparin (Pharmiom). Several other products are available in the European continent including certoparin (Novartis), raviparin (Abbott), nadroparin (Sanofi Synthelabo), and parnaparin (Alphawasserman). Each of these products belong to the class of drugs commonly know as LMWHs and is characterized by molecular weight profile and biologic activity in terms of anti-Xa and anti-Ila ratios. * Until recently these drugs have been provided by original manufacturers and produced under patented manufacturing processes. The mean molecular weight of these drugs ranges from 4000 to 7000 D and the anti-Xa to anti-IIa ratio ranges from 1.5 to 3.5. Each of these agents is also characterized by the presence of specific chemical groupings such as 4,5-unsaturated uronic acid at non-reducing terminus (enoxaparin) and 2,5-anhydro-D-mannose at reducing terminus (dalteparin). While the molecular weight profile is similar for these agents, the component oligosaccharide chains exhibit product specific distribution profile. It is now widely agreed that individual LMWHs are chemically and therapeutically unique agents and can not be interchanged. Additionally each of the commercial LMWHs has been individually developed in specific clinical indications, which may be dosage and product dependent. This may be related to their oligosaccharide composition and molecular profile.
* Several generic versions of branded products such as enoxaparin have become available in India (cutenox and markaparin) and under various other names in South American countries. Two companies in the United States have filed for the regulatory approval to introduce a generic version of enoxaparin. The primary aim of drug interchangeability is to reduce costs without compromising patient care. The generic interchangeability requires substitution of a drug chemically identical and bioequivalent to pioneer drug. Thus for a generic equivalent of a branded drug additional data may be required to prove its identity. * Because LMWHs represent complex natural mucopolysaccharide derived drugs, which have undergone additional chemical and enzymatic modification, specific physicochemical and biologic data may be necessary for the acceptance of generic products. Utilizing a previously reported systematic approach including molecular and structural profiling, potency evaluation in the clot based and amidolytic anti-Xa and anti-IIa assay, interaction with antithrombin-III and heparin cofactor-Il and neutralization profile with heparinase-I, three generic versions of enoxaparin from India and Brazil were compared with branded product available commercially. While the molecular profile (3.93 + 1.4 Kda) and anti-Xa potency was comparable in all these LMWHs, the generic products showed some variations in global anticoagulant assays such as the USP, activated partial thromboplastin time, and Heptest assays. Two of the generic and the branded enoxaparins were readily digested by heparinase-I and lost most of their activities in global anticoagulant assays. However one generic product resisted digestion by heparinase-I and retained most of its biologic activity. This may be due to unique structural feature in this product. Interestingly, protamine sulfate and platelet factor 4 neutralization profile of all four agents was similar.
These studies clearly show that, while generic versions of branded LMWHs may exhibit acceptable molecular weight and anti-Xa profile, these drugs exhibit assay-based differences and heparinase-I digestion profiles. Thus additional testing in animal models for the safety and efficacy and pharmacodynamic parameters may be mandatory. In order to achieve the desired clinical equivalents, there is also a need of developing clear stepwise guidelines including physical, chemical, biochemical, pharmacokinetic/pharmacodynamic equivalence and drug interaction studies to compare the generic versions with the branded products.
Antithrombotic activity must be included in the FDA's assessment of a generic LMWH product, in addition to the pharmacokinetic profile. The bioequivalence or pharmacodynamic data for LMWHs should include: All LMWHs are not equal (6, 7) . Clinicians should stop resisting therapeutic LMWH non-interchangeability, despite cost containment pressures in the hospital setting. Pharmacologic equivalence between LMWHs has not been established (1) . Clinicians who irresponsibly interchange LMWHs are placing their patients at risk by opposing the WHO, FDA, ACC, and AHA (9-11). Furthermore, there may be medicolegal implications for the indiscriminate interchange of the branded drugs for specific indications. This is particularly true for those LMWHs where a dosage for a given indication is objectively established based on valid clinical trials.
On the other hand, generic LMWH interchangeability with the branded products may be more acceptable in the future. It appears that the manufacturing process for LMWHs must be preserved to produce an identical antithrombotic with similar clinical outcomes. The bioequivalence or pharmacodynamic data for LMWHs will need to include antithrombotic markers such as anti-Xa activity, anti-Ila activity, anti-Xa to anti-IIa ratio, PTT, INR, etc. In addition, head-to-head clinical trials in specific indications will also prove the safety and efficacy of the generic LMWH in comparison to the branded LMWH. If a generic company is able to duplicate the original manufacturing process, it is likely that the US FDA will grant generic LMWH approval. One must remember that other complex antithrombotics such as unfractionated heparin sodium (injection) and warfarin (tablets) have been available as generic products in North America for several years.
